ArticleEuropean heart journal open2022
Effectiveness and feasibility of cardiovascular disease personalized prevention on high polygenic risk score subjects: a randomized controlled pilot study.
Article in European heart journal open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07039123 (Polygenic Risk Score to Optimize Primary Prevention in Intermediate Risk Population), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Polygenic Risk Score to Optimize Primary Prevention in Intermediate Risk Population (PERSONAL)
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Are There Any Effective Behavior Change Strategies for Communicating Genetic Risk in Obesity Prevention and Body Weight Reduction Interventions?Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Cardiovascular disease risk communication and prevention: a meta-analysis.European heart journal · 2024Pooled it
- Evaluating the impact of communicating high polygenic risk for coronary artery disease on the health behaviour of young overweight adults: a pragmatic randomised controlled trial.Scientific reports · 2026Trial
- Article
- Polygenic risk scores for cardiovascular disease: clinical utility and limitations.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Feasibility of integrating genetic risk and digital health tools for cardiovascular prevention: the FitPreV protocol.Frontiers in public health · 2026Article
- Effects of polygenic risk score communication on short term health outcomes: systematic review and meta-analysis.BMJ medicine · 2026Article
- A polygenic risk score modifies the cardiovascular risk associated with obstructive sleep apnea.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Is It Time to Abandon the Kidney-Centered View on the Origin of Primary Hypertension?Hypertension (Dallas, Tex. : 1979) · 2025Review
- The impact of supplementing traditional risk information with polygenic risk score concerning type 2 diabetes and coronary heart disease on health behavior: a randomized controlled trial.Journal of community genetics · 2025Article
- Bridging Genomics to Cardiology Clinical Practice: Artificial Intelligence in Optimizing Polygenic Risk Scores: A Systematic Review.JACC. Advances · 2025Review
- The Estonian Biobank's journey from biobanking to personalized medicine.Nature communications · 2025Review
- The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!Global heart · 2025Review
- The current landscape of personalised preventive approaches for non-communicable diseases: A scoping review.PloS one · 2025Article
- Article
- Population Heterogeneity and Selection of Coronary Artery Disease Polygenic Scores.Journal of personalized medicine · 2024Article
- Efficacy of polygenic risk scores and digital technologies for INNOvative personalized cardiovascular disease PREVention in high-risk adults: protocol of a randomized controlled trial.Frontiers in public health · 2024Article
- Engagement of patients and the public in personalised prevention in Europe using genomic information: a scoping review.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The aim of this study was to evaluate the effect of the intervention by proactively sharing a patient's high polygenic risk score (PRS) for coronary artery disease (CAD). Outcomes included: (i) reduction in cardiovascular disease (CVD) risk factors over 12 months; (ii) difference in purchased prescriptions of lipid-lowering and anti-hypertensive drugs between intervention group and control group subjects; and (iii) opinion of the participating physicians and subjects on PRS usefulness. Methods and results: This randomized controlled trial was conducted among middle-aged subjects with a top 20% CAD PRS in a family medicine setting. Participants were selected from 26 953 Estonian Biobank cohort participants. Subjects were informed and counselled about their PRS score and CAD risk using the visual tool at baseline (Visit I), counselling session (Visit II), and on the final Visit III at 12 months. The primary endpoint was not significantly different. However, the intervention group participants had a significantly higher probability of initiating statin treatment compared with the controls. Their levels of LDL-cholesterol (LDL-C) were significantly decreased compared with baseline on Visit III and significantly lower than in the control group. The vast majority of participating family physicians believe that finding out about genetic risks will affect the subject's lifestyle and medication compliance. Conclusion: Most of our outcome measures were in favour of this intervention. Participants achieved larger changes in cholesterol and blood pressure values. The vast majority (98.4%) of family physicians are interested in continuing to use genetic risk assessment in practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.